Ana Castro
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Ana Castro has a total of 30 co-authors. Here are the top co-authors by number of shared publications:
- Aida Orois
Endocrinology and Nutrition Department , Hospital Clínic de Barcelona , Barcelona , Spain
1 shared publication - Alfonso Soto-Moreno
Unidad de Gestión de Endocrinología y Nutrición, Instituto de Biomedicina de Sevilla (IBiS), Hospital Universitario Virgen del Rocío/CSIC/Universidad de Sevilla, 14004 Córdoba, Spain
1 shared publication - Ana Irigaray Echarri
Endocrinology & Nutrition Department, Hospital Universitario Navarra, 31008 Pamplona, Spain
1 shared publication - Andreu Simó-Servat
Department of Endocrinology and Nutrition, Hospital Universitari Mútua Terrassa, Terrassa (Barcelona), Spain
1 shared publication - Andrés Cardona
Endocrinology & Nutrition Department, Hospital Universitario Vall de Hebrón & CIBERER Group 747, 08035 Barcelona, Spain
1 shared publication - Anna Aulinas
Faculty of Medicine, University of Vic-Central University of Catalonia (UVic-UCC), Vic/Manresa , 08500 Catalonia
1 shared publication
Latest Publications
- Open Access
- 25 October 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (21) , 7575
Real-World Data on the Efficacy and Safety of Osilodrostat in Patients with Cushing’s Disease in Spain
Objective: To evaluate the efficacy and safety of osilodrostat in patients with Cushing’s disease (CD). Methods: A retrospective, multicenter, real-world study of patients with CD. The main efficacy endpoint was the proportion of patients who were complete responders (urinary free cortisol [UFC] < the upper limit of normal and/or with adrenal insufficiency development). Results: Thirty-seven CD patients were enrolled. There were 33 patients who initially received osilodrostat in monotherapy and 4 in combination. However, 3 patients of the monotherapy group were switched to combination therapy. The median duration of osilodrostat treatment was 5 months (range 1–93). All the patients were classified as responders: 33 (89.2%) had complete response and 4 partial response. A positive correlation was detected between the percentage of UFC decrease and the maximum (r = 0.481, p = 0.006) and the maintenance doses (r = 0.440, p = 0.011). The initial doses of osilodrostat were a predictor of complete response (vs. partial) (Odds ratio [OR] 2.82, p = 0.030). The median time to UFC normalization in the group of complete responders was 4 weeks (range 1–20) and UFC normalized before or at month 1 in 67% (n = 20/30) of the patients. Osilodrostat led to a significant decrease in systolic and diastolic blood pressure in parallel with a reduction of antihypertensive medications. Conclusions: Osilodrostat leads to a complete UFC normalization in up to 90% of the patients with CD, in parallel with an improvement in the cardiometabolic profile. A proper titration of osilodrostat is important to achieve a complete response since a positive correlation between the doses and the UFC reduction was observed.
- 25 October 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (21) , 7575
Open AccessReal-World Data on the Efficacy and Safety of Osilodrostat in Patients with Cushing’s Disease in Spain
Objective: To evaluate the efficacy and safety of osilodrostat in patients with Cushing’s disease (CD). Methods: A retrospective, multicenter, real-world study of patients with CD. The main efficacy endpoint was the proportion of patients who were complete responders (urinary free cortisol [UFC] < the upper limit of normal and/or with adrenal insufficiency development). Results: Thirty-seven CD patients were enrolled. There were 33 patients who initially received osilodrostat in monotherapy and 4 in combination. However, 3 patients of the monotherapy group were switched to combination therapy. The median duration of osilodrostat treatment was 5 months (range 1–93). All the patients were classified as responders: 33 (89.2%) had complete response and 4 partial response. A positive correlation was detected between the percentage of UFC decrease and the maximum (r = 0.481, p = 0.006) and the maintenance doses (r = 0.440, p = 0.011). The initial doses of osilodrostat were a predictor of complete response (vs. partial) (Odds ratio [OR] 2.82, p = 0.030). The median time to UFC normalization in the group of complete responders was 4 weeks (range 1–20) and UFC normalized before or at month 1 in 67% (n = 20/30) of the patients. Osilodrostat led to a significant decrease in systolic and diastolic blood pressure in parallel with a reduction of antihypertensive medications. Conclusions: Osilodrostat leads to a complete UFC normalization in up to 90% of the patients with CD, in parallel with an improvement in the cardiometabolic profile. A proper titration of osilodrostat is important to achieve a complete response since a positive correlation between the doses and the UFC reduction was observed.